Malaria is arguably one of the main medical concerns worldwide because of the numbers of people affected, the severity of the disease and the complexity of the life cycle of its causative agent, the protist Plasmodium spp. With the advent of nanoscience, renewed hopes have appeared of finally obtaining the long sought-after magic bullet against malaria in the form of a nanovector for the targeted delivery of antimalarial compounds exclusively to Plasmodium-infected cells, thus increasing drug efficacy and minimizing the induction of resistance to newly developed therapeutic agents. Poly(amidoamine) (PAA)-derived nanovectors combine into a single chemical structure drug encapsulating capacity, antimalarial activity, low unspecific toxicity, specific targeting to Plasmodium, optimal in vivo activity, and affordable synthesis cost. After having shown their efficacy in targeting drugs to intraerythrocytic parasites, now PAAs face the challenge of spearheading a new generation of nanocarriers aiming at the malaria parasite stages in the mosquito vector.
(uncertainty range 124-283 million) and the disease led to 584,000 deaths (uncertainty range 367,000-755,000), but an independent study suggests that mortality could be twice as much if untreated and undiagnosed cases are included [7] . People living in the poorest countries are the most vulnerable, with approximately 90% of deaths in Africa, of which 78% were children under 5 years of age [8, 9] . International and domestic funding for malaria control and elimination totaled US$ 2.7 billion in 2013 [5] . Although this represented a threefold increase since 2005, it is still significantly below the estimated US$ 5.1 billion that is required to achieve global targets for control and elimination. Total malaria funding will only match resource needs if international and domestic funders prioritize further investments for malaria control [5] . The current trend of global warming and generalized transcontinental travel, added to the growing number of displaced populations in endemic areas due to political and economic reasons, threatens with expanding the disease range. Malaria eradication is now on the global research agenda [10] , but current vaccines in clinical assays do not offer prospects of complete protection [11] and the available drugs are rapidly losing efficacy. Thus, there is an urgent need to invest in the development of new medicines and therapeutic strategies [12, 13] working through radically new mechanisms. These new approaches should ideally: (i) address drug-resistance issues, (ii) have a rapid onset of action, (iii) be safe, and (iv) cure malaria in a single dose.
Pathophysiology of malaria
Five Plasmodium species cause disease in humans, namely P. vivax, P. ovale, P. malariae, P. knowlesi [14] and P. falciparum, with the latter being responsible for the most deadly and severe cases. When taking a blood meal, the female Anopheles mosquito inoculates Plasmodium sporozoites ( Figure 1 ) that in the liver infect hepatocytes and proliferate into thousands of merozoites [15] . Merozoites invade red blood cells (RBCs), and replicate asexually through ring, trophozoite and schizont stages to produce daughter cells that invade new RBCs to perpetuate the blood-stage cycle. Some parasites eventually differentiate into sexual stages, female or male gametocytes that are ingested by a mosquito from peripheral blood. Following fertilization in the insect's midgut, the zygote differentiates into an ookinete that moves through the midgut epithelium and forms an oocyst, which releases sporozoites. The malaria transmission cycle is restarted when sporozoites migrate to the salivary glands and are injected into a human with the mosquito's next bite. Because the blood-stage infection is responsible for all symptoms and pathologies of malaria, Plasmodium-infected RBCs (pRBCs) are a main chemotherapeutic target [16] . Since antimalarial drug delivery currently relies on compounds with little or no specificity for pRBCs, the administration of most drugs requires high doses. However, such unspecificity often demands a low upper concentration threshold to minimize undesirable side-effects in non-target cells, thus incurring the risk of sublethal doses favoring the evolution of resistant pathogen strains [17] .
Figure 1.
Life cycle of the malaria parasite. Transmission of malaria occurs through a vector, the mosquito, which ingests gametocytes -the sexual form of the parasite-when feeding on an infected human. Male and female gametocytes mate in the mosquito gut, undergo meiosis, and then migrate through the midgut wall to form an oocyst, within which thousands of sporozoites develop. These are then injected into a human during the next blood meal(s), where they rapidly make their way to the liver, infect hepatocytes and begin asexually (mitotically) replicating. After a period of ca. 6-15 days the liver schizonts rupture, releasing thousands of merozoites into the blood where they invade red blood cells, inside which the parasite progresses through a set of stages (ring, trophozoite and schizont) and produces an average of 16 new daughter merozoites per schizont. The schizonts then burst in near synchrony with other parasites, producing the characteristic fever cycle that embodies the clinical manifestations of the disease. With each replication, some of the merozoites develop into gametocytes, which can then infect susceptible mosquitoes, bringing the transmission cycle full circle. From [18] , with permission.
Nanotechnology against malaria
Because malaria pathophysiology is so complex and the disease is so widespread, it is generally accepted that to achieve eradication a combination of weapons will be needed [19] . These include the improvement of existing approaches and the development of new ones [20] , with drug therapy remaining the mainstay of treatment and prevention [21] , and nanotechnology being able to provide innovative useful tools [22] . The objective of delivering drugs exclusively to a selected target site with minimal exposure for adjacent healthy cells or tissues is the holy grail of the fast-developing nanomedicine field [23] . Encapsulation of drugs in targeted nanovectors is a rapidly growing area with a clear applicability to infectious disease treatment [24] , and pharmaceutical nanotechnology has been identified as a potentially essential tool in the future fight against malaria [25, 26] . Nanomedicine, which uses nanosized tools for treatment of disease [27] , can fulfill the objective of achieving the intake of total amounts sufficiently low to be innocuous for the patient, but locally still lethal for the parasite. Mainly because of the lack of economic incentives, the application of nanotechnology to malaria has been traditionally neglected: a search in the Web of Science for the terms "nanomedicine" and "malaria" yields only ca. 30 peer-reviewed publications. The reasons for this gap in nanomedical research are surely varied, but among them are the lack of interest of a profit-seeking industry and the timid support of public administrations to small groups working off the main path of developed world diseases. Actually, the implementation of novel delivery approaches is less expensive than finding new antimalarial drugs and may optimize their rate of release [28] . Current immunoliposomal prototypes engineered for the delivery of antimalarial drugs specifically to pRBCs [29, 30] rely on antibody targeting and contain special lipids, making their synthesis too expensive for practical widespread use in the routine treatment of most malaria cases, which are in regions with limited economic resources. An essential aspect for the successful development of antimalarial nanomedicines resides on the choice of encapsulating and targeting elements, of which it has to be considered their biocompatibility, cell specificity, binding affinity, ease of modification and conjugation to the drugs, production cost, scalability, amenability to oral administration formulation, and stability in mass production. Polymers offer virtually unlimited diversity in chemistry, dimensions and topology, rendering them a class of materials that is particularly suitable for applications in nanoscale drug delivery strategies [31] .
Poly(amidoamine)s
Poly(amidoamines)s (PAAs) are a family of biodegradable and biocompatible polymers whose synthesis was reported more than 40 years ago [32] and since then they have been used in different fields [33] , among which biomedical applications are prominent [34] . The preparation process of PAAs is simple, environmentally friendly and easily scalable, thus being suitable to be commercialized in regions characterized by low per capita income. PAAs can be synthesized by Michael type polyaddition of primary or bis-secondary amines to bis(acrylamide)s (Figure 2 ). The structures obtained present tert-amino and amido groups regularly arranged along the main chain, being in the absence of additional acid or basic substituents low to medium strength polymeric bases that can be classified as polyelectrolytes. PAAs are per se highly functionalized, but are also amenable to further chemical modification for special applications. Groups capable of reacting with activated double bonds under the conditions of PAA synthesis (SH, NH 2 , NR and PH 2 ) cannot be introduced directly but instead they can be obtained by functionalization of purposely pre-synthesized polymers. Amphoteric PAAs derive from aminoacids or from carboxylated bis-acrylamides and carry both carboxyl and amino groups attached to the same monomer, and therefore in solution they change their net average charge as a function of pH. By appropriately choosing the starting monomers, acidic and basic strengths of amino and carboxyl groups can be controlled in a way that the polymer switches from a prevailingly anionic to a prevailingly cationic state as a consequence of relatively modest pH changes [33] . The PAA polymerization reaction takes place in solvents carrying mobile protons, like water or alcohols, without the need for catalysts at room temperature [35, 36] . High temperatures accelerate the polyaddition reaction rate but the resulting polymers have a lower molecular mass because of increased hydrolysis. PAA number-and weight-average molecular masses usually range between 5,000-40,000 and 10,000-70,000 respectively, with a polydispersity index of 1.5-2 depending on the purification method used after synthesis. Narrow polydispersity fractions can be obtained by fractionation techniques, such as ultrafiltration, size exclusion chromatography or field-flow fractionation. Nonamphoteric PAAs are soluble in water, but also in chloroform, lower alcohols, dimethyl sulfoxide and other polar solvents; on the other hand, amphoteric PAAs dissolve only in water. PAAs exhibit relatively large hydrodynamic volumes in solution if compared with vinyl polymers of similar mass, indicating a tendency to assume extended chain conformations in solution [34] . By introducing multifunctional amines in the polymerization mixture crosslinked structures can be obtained, which usually absorb large amounts of water and form hydrogels in aqueous media [37] . These hydrogels have been proven to possess good mechanic properties, biocompatibility, biodegradability and ability to induce cell adhesion and proliferation [38] . In aqueous media PAAs degrade within days or weeks to oligomeric products [39, 40] , in a process strongly influenced by the structure of amide and amine moieties that increases at basic pH and higher temperatures (40-60 °C). The degradation mechanism seems to be purely hydrolytic and not affected by the presence of lysosomal enzymes at pH 5.5 [41] . The toxicity of PAAs and their low molecular mass degradation products is two or more orders of magnitude lower than that of other polycations such as poly-L-lysine, polyethyleneimine or PAMAM dendrimers [34] . Amphoteric PAAs that at pH 7.4 are mostly negatively charged are found to be non toxic, whereas strongly basic polymers positively charged at the same pH display significant cytotoxicity [42] . All PAAs cause more hemolysis at pH 5.5 than at pH 7.4 because protonation of the polymer backbone in acidic conditions increases its capacity to interact with and desestabilize the anionic RBC membrane [43] .
PAA applications in drug delivery
Whereas some PAAs are captured by the liver or the kidney rapidly after i.v. injection [42] , others circulate in the bloodstream for an extended period [44] , showing a tendency to localize in tumours due to the enhanced permeability effect. This long blood residence time is an important feature to consider when selecting candidates for the design of drug delivery systems, since an increased circulation will facilitate interactions of polymers with the target cell, which usually internalizes them via the endocytic pathway [45] . PAAs were first tested for their ability to form polyelectrolyte stable complexes with heparin, in order to neutralise its anticoagulant activity [34, 46] , results later extended to PAA-crosslinked resins, which have also been assayed for metal ion complexation [47] . Depending on their polymer content and formulation, these resins were able to incorporate from 30 to 100% w/w of heparin, without affecting other blood parameters [48] . Early in the 1970s several PAAs were shown to display inherent antitumour activity, reducing the number and average weight of Lewis lung tumour metastases after i.v. administration in mice, with different grades of toxicity and activity, although none of them were active against the primary tumour [49] . More recently, PAAs have been adopted as carriers for anticancer drugs such as mytomycin C [50] , platinates [51] and doxorubicin. Conjugation of doxorubicin to polymers improves drug solubility, increases its blood half-life, decreases its toxicity, and mediates more efficient tumour targeting [52] . As the drug is inactive in its conjugated form and can be selectively released at the tumour site, doxorubicin can act primarily against cancer cells with minimal damage to healthy tissue. Doxorubicin has also been coupled to polymers via an acid-sensitive linker, facilitating the release of the drug in a biologically active form in the endosomal compartment [53] .
As a promising tool to treat a variery of diseases, PAAs have been used as carriers for RNA and DNA as transfection promoters [54] [55] [56] [57] . In particular, PAA polymers synthesized from bisacrylamides and incorporating a carboxylic acid group have been reported to achieve transfection efficiencies comparable to polyethyleneimine, the gold standard for polymer-assisted gene transfection, but with a significantly lower cytotoxicity [56] . Different modifications of PAAs have been published, for instance incorporating repetitive disulfide links in the main chain [58] , linear or branched architectures [59] , intercalating quaternary nicotinamides [55] and boronic acid moieties [54] as side groups, in order to combine stability of the polyplexes, high transfection efficiencies and low unspecific cytotoxicity [60] . In vitro assays demonstrated the ability of the polymers to form stable polyplexes, to interact with cell membranes in a non-disruptive way, to protect DNA from enzymatic degradation in the biological environment and to promote stable gene transfection in living cells [61] . PAAs have been found to be particularly suitable for the intracellular delivery of peptides and proteins [62, 63] , which can be inserted for targeting purposes either as pendants or as integral portions of the polymer chain. Different functionalized PAAs have been optimized to obtain a fast and efficient protein release with lysozyme as a model cationic protein [63] or with β-galactosidase, which was successfully taken up into cells, whereas the enzyme alone could not be internalized [64] . These polymer-protein complexes are stable in extracellular media but disintegrate into low molecular mass fragments once inside the cells. The (partial) release of proteins from the complexes is induced by charge reversal at endosomal pH, leading to decreased protein-polymer interaction, and by polymer degradation due to intracellular reduction of polymer disulfide linkages. Endosomal escape of the nanovessel and its cargo will depend on the different functionalities present in the polymer [65] , e.g. positively charged groups are expected to have increased interactions with the membrane of the organelle and promote endosomal disruption [58] . Other PAA derivatives, such as branched polymers with arginine, maintain the cell internalization capacity of the amino acid, but having increased biocompatibility than argininerich cell penetrating peptides [66] . PAAs have been used as carriers for the antiviral compound Acyclovir [67] , where in vitro experiments showed that polymer conjugation of the drug increased its activity. More recent results [68, 69] , indicate that agmatine-containing PAAs possess antiviral activity which is not a mere consequence of cytotoxicity.
PAAs for the targeted delivery of antimalarial drugs
The PAA structures AGMA1, ISA1 and ISA23 (Figure 3 ) have been explored for the encapsulation and targeted delivery of the antimalarial drugs chloroquine and primaquine [70] . AGMA1 is obtained by polyaddition of 4-aminobutylguanidine (agmatine) with 2,2-bis(acrylamido)acetic acid and contains tert-amine, carboxyl and guanidine groups. It is amphoteric with isoelectric point 10.0 and therefore at pH 7.4 is prevailingly cationic with, on average, 0.55 excess positive charges per unit. ISA23 is obtained by polyaddition of 2-methylpiperazine with 2,2-bis(acrylamido)acetic acid. Notwithstanding carrying two tert-amine groups and one carboxyl group per unit, it has isoelectric point 5.5, being prevailingly anionic at pH 7.4 with, on average, 0.38 excess negative charges per unit. ISA1 is obtained by polyaddition of bis(acryloyl)piperazine with 2-methylpiperazine and bis(hydroxyethylethylenediamine). It is a rather weak polymeric base with, on average, 0.55 positive charges per unit at pH 7.4. All these polymers had been reported as vectors for the intracellular delivery of nucleic acids [56, 61, 71] , whereas ISA1 and ISA23 had been also studied for protein delivery [45, 62, 71] and as anticancer drug carriers [51, 53] . ISA23 in particular has been proven to be endowed with stealth-like properties without selectively concentrating in the liver [44] , while a significant portion of AGMA1 did show hepatic localization after intravenous injection in mice [42] . In intracellular compartments where the pH decreases to 6.5 (endosomes) and then to 5.0 (lysosomes), PAAs become prevailingly cationic and display endosomolytic properties [72] . Fluorescence microscopy revealed colocalization of ISA1 and ISA23 with Lysotracker, a marker for lysosome and late endocytic structures, and ISA1 also colocalized with the Early Endosomal Antigen 1 that accumulates in early endocytic structures [45] . Atomic force microscopy images (Figure 4 ) revealed a globular conformation for AGMA1, ISA23 and ISA1 adsorbed on mica substrates, showing a homogenous polymer size distribution with a hydrodynamic radius between 6 and 7 nm according to size exclusion chromatography analysis [70] . pRBCs are known to be permeable to high molecular mass solutes up to diameters of 70 nm [73, 74] , including peptides and proteins, with which PAAs share some features, such as the polyelectrolyte behavior and the presence of amide groups in the main chain. This led us to explore the potential of ISA1, ISA23 and AGMA1 as antimalarial drug carriers. Fluorescence-assisted cell sorting, confocal immunofluorescence and transmission electron microscopy results indicated that the tested polymers have specific targeting to pRBCs, and subcellular targeting to the parasite itself ( Figure 5 ). In 4-day suppressive tests, mice infected with a lethal strain of the murine malaria species Plasmodium yoelii were freed of parasites and cured after intraperitoneal administration of chloroquine encapsulated in AGMA1 or ISA23 at a dose of 0.8 mg kg -1 day -1 , whereas the same amount of free drug was unable to cure the animals [70] . PAAs targeted different Plasmodium species and AGMA1 in particular possessed significant intrinsic antimalarial activity per se, showing binding to merozoites and probably inhibiting their invasion of new red blood cells. The ensuing prolonged exposure of the pathogens to the immune system might be applied to the design of new malaria vaccination approaches where PAAs could play a dual role as carriers of antimalarial drugs and as vaccination adjuvants. This unexpected synergistic effect combining therapeutics and prophylaxis represents a radically new approach to the treatment of malaria for which we propose the term theralaxis. Figure 5 . Confocal fluorescence microscopy targeting study of AGMA1 and ISA23 to P. falciparum and P. yoelii. FITC-labeled ISA23 (A) or AGMA1 (B) were added to either P. yoeliiinfected mouse blood, or to living P. falciparum cultures of the 3D7 strain, respectively. After 90 min of incubation the samples were processed for confocal fluorescence microscopy analysis. PAA-FITC localization is shown in green, DAPI (blue) staining of Plasmodium nuclei was used to reveal the parasites, and the RBC plasma membrane is shown in red. From [70] , with permission.
Antimalarial drug delivery to mosquitoes
Current chemotherapeutic approaches against malaria are targeted at the asexual, blood-stage parasites responsible for all symptoms and pathologies of the disease [16] . However, as in the bloodstream of a malaria patient there can be several hundred billion pRBCs, multiple-dose administrations of drugs are usually required to clear infections. This continuous exposure of Plasmodium to antimalarials increases the likelihood of resistance evolution, which will rapidly decrease drug efficacy. The threat of resistance-driven treatment failure is prompting research oriented to targeting the weakest forms of the pathogen represented by smaller populations, which are less likely to contain resistant individuals that would benefit from the removal of susceptible parasites [75] . The two main bottlenecks in the malaria cycle are found where the parasite is in one of the transmission stages that move between hosts [76] . A few thousand sporozoites can be packed inside the mosquito salivary glands, but only approximately 100 will be transferred to the human when Anopheles bites; this is several orders of magnitude fewer parasites than are found in an active blood stage infection. However, the short time that free sporozoites remain in the circulation is a serious obstacle to targeting them. A second bottleneck occurs during sexual development, when ca. 0.2-1% of the intraerythrocytic parasites may develop into gametocytes per round of schizogony. Although this still leaves an estimated 10 8 -10 9 parasites to be cleared from the blood circulation, targeting gametocytes can ease exposure of the pathogen to drugs and reduce the likelihood of resistance emerging [76] . However, a largely unexplored avenue in antimalarial drug development is targeting the parasite stages in the insect vector itself [77] , an approach being barely investigated in the laboratory, and not implemented yet as part of a clinically feasible alternative therapy. Although the innate immune system of mosquitoes is capable of completely clearing a malaria infection [78] , it is far from the sophisticated arsenal providing long-term protection in mammalian adaptive immunity. This might result in mosquito stages of Plasmodium having reduced defenses because they need to survive just a few days facing an immune surveillance not as demanding as in the human host. In addition, the richness of biological processes required for development in the mosquito likely withdraws from the parasite metabolic resources otherwise allocated to drug resistance. Drugs targeting early Anopheles stages must kill only ca. 5  10 3 parasites to free a mosquito from Plasmodium infection [79] , and the absolute low corresponds to oocysts, of which there are only 2-5 in a single insect [76] , being around for over a week. The recent appreciation that decreasing malaria prevalence requires strategies to reduce transmission through the mosquito [80] has prompted a renewed search for alternative therapeutic approaches. Unlike the asexual parasites, Plasmodium transmission forms are difficult and expensive to propagate and handle in the laboratory, but the first practical steps that shall eventually make possible these new objectives are being taken in the form of incipient protocols for the purification of P. falciparum ookinetes [81] , although their culture has not been standardized [82, 83] . P. vivax ookinetes can be grown in culture [84] , but implementation of this assay would require both the stable transfection of the parasite, a process not yet achieved [85] , and the routine availability of viable gametocytes en masse, currently not possible from culture. Gametocyte-to-ookinete development can be reproduced successfully in vitro for the rodent malaria parasite P. berghei [86] . However, these alternative cell targets incur the significant problem of their in vivo location in the mosquito.
Two approaches seem to offer some hope of being able to deliver transmission-blocking drugs to Anopheles, but it is difficult to say which one poses more daunting obstacles. Because gametogenesis, fertilization, and zygote differentiation into an ookinete occur in the mosquito within an environment essentially consisting of human blood, any compound affecting these processes can be delivered via the very blood meal of the insect. Thus, we can consider administering to humans antimalarials with a sufficiently long blood half-life to have good chances of being taken up by a mosquito during its bite. According to approximate estimates this might mean between 3 or 4 weeks in the blood of people living in endemic areas. In addition to patient compliance, we face the challenge of finding a drug escaping spleen and liver clearance and kidney filtration for a formidably long time span, and which in the end has to be present at therapeutic concentration in the infected insect. To the best of our knowledge, the only example of drug administration in this way to mosquitoes is the case of ivermectin [87] , an insecticide which, at concentrations found in human blood after treatment, is toxic to all Anopheles species examined. However, the insect has to blood-feed on a treated subject (i.e. patient compliance is a parameter to consider), and resistances to ivermectin have been already documented [88] .
Direct antimalarial drug administration to mosquitoes
The alternative to administering antimalarials to mosquitoes via human blood through the insect's blood meal is even more mind-boggling: delivering the drug directly to Anopheles. For this approach to work it is a must that the mosquito should have the need to ingest something between a first blood meal where gametocytes have been taken and the second infective bite once Plasmodium sporozoites have developed. There seems to be a lack of consensus as to whether during that time lapse Anopheles either rests in a secluded spot, or it does eventually drink some substance. But even if the mosquito is satiated for weeks following a blood meal, the very biology of the malaria parasite might assist us here. To keep blood fluid and prevent quick coagulation, Anopheles synthesizes an anti-hemostatic armamentarium containing, among others, the enzyme apyrase. Plasmodium inhibits apyrase [89] and in this way entices the mosquito to bite more because blood coagulates faster and Anopheles has to probe longer to get its full dinner, thereby increasing potentially infective host contacts. It can be expected then that infected insects will have a larger probability of probing a non-human source.
While female mosquitoes depend on protein-rich blood meals for egg maturation, both male and female mosquitoes are also attracted to and feed from plants. Plant nectar is an important, carbohydrate-rich nutrient source that provides essential energy for flight and, for some mosquito species, overwintering [90, 91] . This phytoattraction has been successfully harnessed by malaria control efforts through attractive nectar baiting strategies, in which mosquitoes are lured to sugarwater blends spiked with plant volatiles and insecticides [92, 93] . Suspected preferred host plants for Anopheles gambiae include Asteracaeae spp. and Ricinus communis [94] . Analysis of purified odorants from these plants has revealed enrichment of volatile compounds known as terpenes, including 10-carbon monoterpenes such as pinene and limonene, which at low concentrations have been shown to mediate attraction of Anopheles spp. [94, 95] . Several approaches are currently available for oral delivery to mosquitoes by droplet or liquid feeding, through dry diets [96] , or via nylon strips continuously dispensing synthetic mosquito attractants for several weeks [97, 98] . Some of these methods have been already used to deliver to dipterans lipid-based [99] and chitosan nanoparticles [100] . Because Anopheles males can be easily fed from drug-containing sugar-baited traps, unlike females whose blood meal feeding habits complicate the design of a surrogate blood diet, it would be advisable to investigate the possible horizontal transfer of antimalarial drugs through sperm. Another interesting, though challenging, alternative to administering PAAencapsulated drugs to adult mosquitoes with the objective of eliminating Plasmodium from infected insects, is delivery to mosquito eggs. In such strategy, if PAA nanocarriers can be made to persist throughout metamorphosis, emerging mosquitoes might be endowed with prophylactic antimalarial capacity. A number of chemicals have been proposed as oviposition attractants for A. gambiae [101, 102] , with the sesquiterpene alcohol cedrol as one of the most promising candidates [103] .
Highly concentrated drugs against Plasmodium gametes, ookinetes, oocysts or sporozoites could be directly dispensed to mosquitoes from fixed-volume containers where the drug does not become diluted with time as when it circulates in human blood. Such a strategy, because it is not designed for administration to humans, will bypass clinical trials that often delay for years the deployment of a new medicine, and will significantly reduce treatment development costs. Mosquito-dwelling transmission forms will likely be efficiently reached by specifically targeted nanovectors encapsulating the corresponding drugs, which in this way are protected from degradation before being ingested by the insect. A final bonus of delivering the nanocarriers directly to mosquitoes is that the usable nanoparticle size range becomes greatly expanded between a few nm and up to several microns for the direct delivery to females. Administration to insects will allow also for a not so strict vigilance on other nanocarrier characteristics such as zeta potential, toxicity of the chemical units constituting the nanovector, the nature, type and number of targeting units, or the nature, number, and amount of drug(s) loaded.
Targeting mosquito stages of Plasmodium
The three elements that constitute a targeted therapeutic nanovector (nanocapsule, targeting molecule and the drug itself) can be exchanged, as if they were LEGO parts, to obtain new structures better suited to each particular situation. Through modification of its constituting elements, nanovector design is susceptible of improvement and of adaptation to new targets such as different Plasmodium species or infected cells other than the erythrocyte. Of particular interest here, as discussed above, is the targeting of the transmission stages that allow transfer of the parasite between human and mosquito and vice-versa, which represent the weakest spots in the life cycle of the pathogen [77] . Heparin and heparan sulfate are targets for the circumsporozoite protein in the sporozoite attachment to hepatocytes during the primary stage of malaria infection in the liver [104] . Chondroitin sulfate proteoglycans in the mosquito midgut and synthetic chondroitin sulfate mimetics have been described to bind Plasmodium ookinetes as an essential step of host epithelial cell invasion [105, 106] , whereas ookinete-secreted proteins have been found to possess significant binding to heparin [107] . A synthetic polysulfonated polymer that mimics the structure of glycosaminoglycans present in the mosquito midgut surface has been used as a proof of concept for a transmission-blocking strategy [106] . The authors showed that the inhibition of Plasmodium development in the mosquito could be achieved by interfering in the interaction between the parasite and the mosquito midgut epithelium, which is a key step in the life cycle of the pathogen. This body of accumulated evidence suggests that glycosaminoglycans might be adequate to target antimalarial-loaded PAA-based nanovectors to Plasmodium mosquito stages, either through a direct entry into gametocytes, ookinetes, and sporozoites, or indirectly through delivery to pRBCs for those that will later differentiate into gametocytes.
Phenomenal experimental obstacles loom above this approach, which could only be pushed forward with a truly multidisciplinary research team involving chemists, physicians, entomologists, environmentalists, biochemists, evolutionary biologists, nanotechnologists, and many other professionals. Although eliminating a handful of oocysts in a bug seems easy enough, the sheer numbers of mosquitoes that have to be reached represents a challenge that will require a deep understanding of insect behavior and, likely, the development of new antimalarial drugs working through radically new mechanisms. But, if we take the pain of targeting the mosquito, wouldn't it be better just delivering insecticide? However, by wiping off an insect species we might be unbalancing the ecosystem in unpredictable ways, not to mention that besides Anopheles, the concocted broth can be a delicatessen for many other insects, some of them with known essential functions e.g. as pollinators, whose eradication might bring crop collapse and famine.
Future perspective
Future antimalarial strategies relying on drugs working through radically new mechanisms might demand direct delivery to Plasmodium stages in the mosquito of PAA-based targeted nanovectors loaded with these new medicines. The specifications to which the nanocarriers will likely have to fit are (i) a simple and scalable synthesis with affordable cost, (ii) the capacity to encapsulate a wide range of antimalarial drug structures, (iii) a long half-life of months without losing integrity before being ingested by the mosquito while preserving drug activity, (iv) an adequate degradation rate once inside female Anopheles to allow the drug entering Plasmodium, (v) a slower degradation rate once inside male Anopheles to allow the nanocarriers being horizontally transferred to females upon mating, (vi) a high solubility in mosquito artificial diets to allow for the maximum affordable concentrations, and (vii) a targeting as specific as possible to Plasmodium stages inside Anopheles (gametocytes, ookinetes, oocysts and sporozoites). As we have discussed above, PAA-based nanocarriers can fulfill these requirements and thus significantly contribute as a new weapon in a future scenario of malaria eradication.
Executive summary
Malaria: a main health concern with an economic bias • There is an urgent need to invest in the development of new antimalarial medicines and therapeutic strategies working through radically new mechanisms. Pathophysiology of malaria • The unspecificity of toxic drugs demands low concentrations to minimize undesirable side-effects, thus incurring the risk of sublethal doses favoring the evolution of resistant Plasmodium strains. Nanotechnology against malaria • Drug therapy remains the mainstay of treatment and prevention against malaria, with nanotechnology being able to provide innovative useful tools.
• Pharmaceutical nanotechnology has been identified as a potentially essential tool in the future fight against malaria.
• Nanomedicine can fulfill the objective of achieving the intake of total amounts sufficiently low to be innocuous for the patient, but locally still lethal for the parasite.
• Mainly because of the lack of economic incentives, the application of nanotechnology to malaria has been traditionally neglected.
• The development of novel delivery approaches is less expensive than finding new antimalarial drugs. Poly(amidoamine)s • The preparation process of PAAs is simple, environmentally friendly and easily scalable, thus being suitable to be commercialized in regions characterized by low per capita income.
PAA applications in drug delivery
• PAAs have been found to be particularly suitable for the intracellular delivery of peptides and proteins. PAAs for the targeted delivery of antimalarial drugs • PAAs have been shown to be targeted to Plasmodium. Antimalarial drug delivery to mosquitoes • A largely unexplored avenue in antimalarial drug development is targeting the parasite stages in the insect vector itself. Direct antimalarial drug administration to mosquitoes • Drug delivery to mosquitoes, because it is not designed for administration to humans, will bypass clinical trials that often delay for years the deployment of a new medicine. Targeting mosquito stages of Plasmodium • Glycosaminoglycans might be adequate to target antimalarial-loaded PAA-based nanovectors to Plasmodium mosquito stages.
